8-K: Leap Therapeutics Secures $58.88M for Digital Asset Pivot

Leap Therapeutics closed a $58.88 million private placement led by Winklevoss Capital to fund a new digital asset treasury strategy and advance therapeutic programs.

Summary

• Leap Therapeutics, Inc. completed a private placement on October 8, 2025, raising approximately $58.88 million in gross proceeds.
• The private placement included the issuance of 15,212,311 shares of common stock at $0.52064 per share.
• Pre-funded warrants to purchase up to 80,768,504 shares of common stock were issued at $0.51964 per warrant, with an exercise price of $0.001 per share.
• Common warrants to purchase up to 71,985,605 shares of common stock were issued at an exercise price of $0.5335 per share, expiring on the tenth anniversary of issuance.
• Winklevoss Treasury Investments, LLC acted as the lead investor, providing both capital and strategic support for the new digital asset treasury strategy.
• A portion of the proceeds will continue to fund the development of therapeutic programs, including FL-501 and sirexatamab, with sirexatamab having completed a Phase 2 trial in colorectal cancer.
• The company plans to use a significant portion of the proceeds for a new business line involving investment in and trading of a 'Token' (digital asset), digital asset treasury activities, staking, and validation.
• Parcrest International served as the placement agent, receiving $1.0 million in cash and warrants to purchase 4,000,000 shares of common stock.
• The Board of Directors was expanded to 12 members, granting Winklevoss Treasury Investments, LLC the right to nominate two directors, one of whom will serve as Board Chair, contingent on beneficial ownership thresholds.

Sentiment

Score: 6

Explanation: The significant capital raise is a strong positive, providing substantial funding for both existing therapeutic programs and a new strategic direction. However, the pivot to a digital asset treasury strategy introduces high volatility and regulatory uncertainty, which are substantial new risks for a biotechnology company, leading to a mixed sentiment.

Positives

• Successfully raised approximately $58.88 million in gross proceeds through a private placement, significantly bolstering the company's capital position.
• Secured a strategic partnership with Winklevoss Capital, a prominent investor in frontier technologies, lending credibility and expertise to the new digital asset strategy.
• The capital infusion will support the continued development of existing therapeutic programs, including FL-501 and sirexatamab, which recently completed a Phase 2 trial.
• The establishment of a new digital asset treasury strategy opens a potential new avenue for value creation and diversification for the company.

Negatives

• The significant pivot to a digital asset treasury strategy introduces a new and highly volatile business segment, potentially distracting from the core biotechnology focus.
• The success of the digital asset strategy is subject to significant market, regulatory, and technical uncertainties, which are outside the company's traditional area of expertise.

Risks

• Failure to realize the anticipated benefits of the proposed digital asset treasury strategy.
• Changes in business, market, financial, political, and regulatory conditions, particularly impacting digital assets.
• The highly volatile nature of cryptocurrency prices, which could negatively impact the company's financial health.
• The price of the company's common stock may become highly correlated to the price of the digital assets it holds.
• Increased competition in the industries in which the company does and will operate, including the digital asset space.
• Significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally.
• Risks relating to the treatment of crypto assets for U.S. and foreign tax purposes.
• General risks and uncertainties identified in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company intends to use net proceeds from the private placement to pursue a new digital asset treasury strategy, involving investment in tokens, digital asset treasury activities, staking, and validation. A portion will also continue to fund therapeutic programs, including FL-501 and sirexatamab. The company expects to release additional updates regarding its treasury activities in the near-term.

Management Comments

• Winklevoss Capital will provide both capital and strategic support to help Leap structure and execute its digital asset treasury strategy.
• Leveraging the expertise of Winklevoss Capital, Leap aims to build long-term shareholder value through participation in digital assets.

Industry Context

This announcement marks a significant and unusual strategic shift for Leap Therapeutics, a biotechnology company, into the digital asset space. While traditional biotech companies focus on drug discovery, development, and commercialization, Leap is diversifying its treasury strategy to include highly volatile digital assets. This move positions the company at the intersection of two distinct and often uncorrelated industries, potentially offering new growth avenues but also introducing a complex and elevated risk profile not typically associated with the pharmaceutical sector. The involvement of Winklevoss Capital, a known entity in the digital asset space, suggests a serious commitment to this new direction, but the long-term implications for a biotech company operating with a digital asset treasury remain to be seen in an evolving regulatory and market landscape.

Comparison to Industry Standards

• The adoption of a primary digital asset treasury strategy by a biotechnology company like Leap Therapeutics is highly unconventional and deviates significantly from standard industry practices in the biotech sector.
• Traditional biotechnology companies typically maintain treasury assets in cash, cash equivalents, and conservative short-term investments to fund research and development, clinical trials, and operational expenses, prioritizing capital preservation and liquidity.
• There are no widely recognized comparable publicly traded biotechnology companies that have adopted a primary digital asset treasury strategy, making direct industry benchmarks for this specific strategic pivot unavailable.
• The move introduces a risk profile more akin to a cryptocurrency investment vehicle or a technology company heavily invested in digital assets, rather than a pharmaceutical developer, which is a stark contrast to global biotech industry standards.

Management Changes

Corporate Governance

Related Party Transactions

• Winklevoss Treasury Investments, LLC (Lead Investor) participated in the private placement and gained board nomination rights.

Stakeholder Impact

• Shareholders: Potential for significant value creation from the digital asset strategy, but also exposure to high volatility and new risks. Dilution from the issuance of new shares and warrants.
• Employees: Continued funding for therapeutic programs ensures job security and progress in existing R&D efforts. New opportunities may arise from the digital asset venture.
• Customers (patients): Continued development of therapeutic programs like FL-501 and sirexatamab could lead to new treatment options.
• Creditors: The capital raise improves the company's liquidity and financial standing, potentially reducing credit risk, but the new digital asset strategy introduces new financial risks.

Next Steps

• Continue development of therapeutic programs, including FL-501 and sirexatamab.
• Initiate and execute the recently announced digital asset treasury strategy, including investment in tokens, digital asset treasury activities, staking, and validation.
• Release additional updates regarding treasury activities in the near-term.
• File a registration statement for the resale of the issued securities within 30 days of written demand by any purchaser.

Key Dates

Recommendation

The substantial capital raise of $58.88 million is a positive development, providing significant funding for both existing therapeutic programs and a new strategic direction. The involvement of Winklevoss Capital also lends some credibility to the digital asset venture. However, the company's pivot into a primary digital asset treasury strategy introduces a high degree of volatility, regulatory uncertainty, and a fundamentally different risk profile for a biotechnology company. This dual business model makes the investment highly speculative. For existing investors, holding to observe the execution and initial results of the digital asset strategy, alongside continued therapeutic development, is a reasonable approach. For new investors, the high-risk, high-reward nature warrants careful consideration and due diligence before making a decision.

Keywords

Leap Therapeutics, Winklevoss Capital, Private Placement, Digital Asset Treasury, Cryptocurrency, Biotechnology, FL-501, Sirexatamab, Warrants, Common Stock, SEC Filing, Capital Raise, Corporate Governance